Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.

Bassem I YamoutNabil K El-AyoubiJohny NicolasYehya El KouziSamia Joseph KhouryMaya M Zeineddine

Published in: Journal of immunology research (2018)

In our real-world cohort, rituximab was well-tolerated and effective in reducing relapse rate and disability progression in relapsing-remitting and progressive MS patients.

Keyphrases

multiple sclerosis
white matter
end stage renal disease
diffuse large b cell lymphoma
newly diagnosed
ejection fraction
chronic kidney disease
hodgkin lymphoma
mass spectrometry
rheumatoid arthritis
systemic lupus erythematosus
chronic lymphocytic leukemia
patient reported outcomes